Kraig Biocraft Laboratories Establishes Homozygosity and Confirms BAM 1 Hybrid Optimized Ahead of Spring Production Trials
ANN ARBOR, Mich., Feb. 27, 2024 (GLOBE NEWSWIRE) -- Kraig Biocraft Laboratories, Inc. (OTCQB: KBLB) ("Kraig Labs" or "the Company"), announces that it has achieved homozygosity for the spider silk gene in both of the parental strains for its new production hybrid. Establishing homozygosity for the targeted gene in both parental strains means that the Company's new BAM 1 hybrid production system is optimized for recombinant spider silk production.
The BAM 1 hybrid represents the Company's latest innovation in the commercialization of recombinant spider silk technology. Achieving homozygosity for both BAM 1 parental strains is another significant milestone in the commercialization of recombinant spider silk. The reason homozygosity is important is because it results in higher levels of spider silk protein expression.
"Our team set an aggressive deadline for achieving homozygosity in the BAM 1 hybrid ahead of our spring production trials," said CEO and Founder, Kim Thompson. "Today, I am pleased to report they met that goal and that BAM 1 hybrids, which will be our primary production strain for the upcoming production season, is now optimized for recombinant spider silk expression. Our team continues to hit its marks, and I am looking forward to a very exciting year for Kraig Labs and the commercial launch of our revolutionary spider silk technology."
To view the most recent news from Kraig Labs and/or to sign up for Company alerts, please go to www.KraigLabs.com/news
About Kraig Biocraft Laboratories, Inc.
Kraig Biocraft Laboratories, Inc. (www.KraigLabs.com), a reporting biotechnology company is the leading developer of recombinant spider silk-based fiber technologies.
The Company has achieved a series of scientific breakthroughs in the area of spider silk technology with implications for the global textile industry.
Cautionary Statement Regarding Forward Looking Information
Statements in this press release about the Company's future and expectations other than historical facts are "forward-looking statements." These statements are made on the basis of management's current views and assumptions. As a result, there can be no assurance that management's expectations will necessarily come to pass. These forward-looking statements generally can be identified by phrases such as "believes," "plans," "expects," "anticipates," "foresees," "estimated," "hopes," "if," "develops," "researching," "research," "pilot," "potential," "could" or other words or phrases of similar import. Forward looking statements include descriptions of the Company's business strategy, outlook, objectives, plans, intentions and goals. All such forward-looking statements are subject to certain risks and uncertainties that could cause actual results to differ materially from those in forward-looking statements. This press release does not constitute an offer to sell or the solicitation of an offer to buy any security.
Ben Hansel, Hansel Capital, LLC
(720) 288-8495
ir@KraigLabs.com
-
For Bond Investors, Delayed Rate Cuts Demand a Different Playbook
-
What’s Happening In the Markets This Week
-
How the Tokyo Stock Exchange Is Pushing for Better Shareholder Returns
-
Magnificent 7 Stocks Earnings Updates: AI Remains the Focus
-
Where We See Opportunities After an Ugly Month for Stocks
-
After Earnings, Is Alphabet Stock a Buy, a Sell, or Fairly Valued?
-
When Will the Fed Start Cutting Interest Rates?
-
What’s the Difference Between the CPI and PCE Indexes?
-
Berkshire Hathaway Earnings: Strong Insurance Results Continue to Lift Revenue and Profitability
-
10 Questions for Berkshire Hathaway’s 2024 Annual Meeting
-
After Earnings, Is Ford Stock a Buy, a Sell, or Fairly Valued?
-
3 Dividend Stocks for May 2024
-
Amgen Earnings: Obesity Drug Update Is Highly Encouraging
-
What’s Going on With Apple, Tesla, and Alphabet?
-
Apple Earnings: A Weak 2024, but Optimism for 2025
-
4 Utility Stocks to Play the AI Data Center Boom